Company CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:12:11 2024-12-03 pm EST			5-day change	1st Jan Change
51.38 ^USD	-6.84%		+4.44%	-17.73%

Nov. 05	CRISPR Therapeutics' Q3 Net Loss Narrows	MT
Nov. 05	Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q3 Revenue $602,000	MT

Business description: CRISPR Therapeutics AG

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Number of employees: 407

Sales by Activity: CRISPR Therapeutics AG

Fiscal Period: December	2019	2020	2021	2022	2023
Biotechnology	290M	719K	915M	1.2M	371M

See all business segments

Managers: CRISPR Therapeutics AG

Director	Title	Age	Since
Samarth Kulkarni CEO	Chief Executive Officer	45	2017-11-30
Raju Prasad DFI	Director of Finance/CFO	40	2023-03-13
Julianne Bruno COO	Chief Operating Officer	38	2024-05-22
Stephen Kennedy CTO	Chief Tech/Sci/R&D Officer	67	2019-09-30
Jonathan Terrett CTO	Chief Tech/Sci/R&D Officer	-	-

See CRISPR THERAPEUTICS AG governance

Members of the board: CRISPR Therapeutics AG

Manager	Title	Age	Since
Simeon George BRD	Director/Board Member	47	2015-04-28
Ali Behbahani BRD	Director/Board Member	45	2015-03-31
Samarth Kulkarni CHM	Chairman	45	2023-09-14
Katherine High BRD	Director/Board Member	72	2019-06-10
John Greene BRD	Director/Board Member	58	2019-06-10
Doug Treco Treco BRD	Director/Board Member	66	2020-06-10
Harold Edward Fleming BRD	Director/Board Member	61	2021-06-09
Maria Fardis BRD	Director/Board Member	56	2022-06-08
Christian Rommel BRD	Director/Board Member	57	2024-03-12
Sandy Mahatme BRD	Director/Board Member	59	2024-05-29

Composition of the Board of Directors

Shareholders: CRISPR Therapeutics AG

Name	Equities	%	Valuation
Capital Research & Management Co. (International Investors) 9.307 %	7,926,734	9.307 %	368 M $
ARK Investment Management LLC 8.804 %	7,498,625	8.804 %	348 M $
STATE STREET CORPORATION 3.514 %	2,992,988	3.514 %	139 M $
SUMITOMO MITSUI TRUST HOLDINGS, INC. 3.485 %	2,968,034	3.485 %	138 M $
Nikko Asset Management Americas, Inc. 3.484 %	2,967,219	3.484 %	138 M $

List of CRISPR THERAPEUTICS AG shareholders

Company details: CRISPR Therapeutics AG

CRISPR Therapeutics AG

Baarerstrasse 14

6300, Zug

+41 41 561 32 77

http://www.crisprtx.com

Other Biotechnology & Medical Research

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
CRISPR THERAPEUTICS AG	-6.84%	+4.44%	-27.98%	-26.52%	4.71B
LONZA GROUP AG	-0.72%	-1.13%	+59.04%	-26.92%	43.09B
IQVIA HOLDINGS INC.	-1.16%	-0.71%	-7.61%	-23.65%	36.62B
CELLTRION, INC.	+1.25%	+5.71%	+14.59%	-6.92%	27.11B
ICON PUBLIC LIMITED COMPANY	-0.10%	+0.80%	-19.79%	-21.61%	17.63B
MODERNA, INC.	-2.45%	+2.33%	-46.12%	-85.97%	17.03B
UNITED THERAPEUTICS CORPORATION	-0.15%	-1.85%	+54.22%	+98.95%	16.52B
BIO-TECHNE CORPORATION	-1.21%	+0.13%	+14.81%	-34.26%	12.08B
MEDPACE HOLDINGS, INC.	-0.68%	+1.80%	+22.09%	+65.55%	10.62B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.19%	+0.82%	-0.61%	-44.21%	10.29B
Average	-1.36%	+1.94%	+6.26%	-10.56%	19.57B
Weighted average by Cap.	-0.86%	+1.14%	+13.78%	-13.91%